RE
PTLA

RBC Europe’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

RBC Europe’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-500
Closed -$9.76K – 1117
2018
Q4 		$9.76K Hold
500
– – ﹤0.01% 793
2018
Q3 		$13.3K Hold
500
– – ﹤0.01% 772
2018
Q2 		$18.9K Hold
500
– – ﹤0.01% 683
2018
Q1 		$16.3K Hold
500
– – ﹤0.01% 714
2017
Q4 		$24.3K Hold
500
– – ﹤0.01% 630
2017
Q3 		$27K Buy
+500
New +$29.4K ﹤0.01% 617

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

RBC Europe's PTLA Position: Q1 2019 in Review

RBC Europe sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2019, closing a stake of 500 shares — an estimated $9.76K sold.

RBC Europe first reported a position in PTLA in Q3 2017 and held it in 6 quarters. The position peaked at $27K in Q3 2017. 209 funds tracked by Wall St. Rank hold PTLA as of Q1 2019.

  • RBC Europe reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • RBC Europe sold 500 Portola Pharmaceuticals, Inc. shares in Q1 2019, an estimated $9.76K.
  • RBC Europe first reported a position in Portola Pharmaceuticals, Inc. in Q3 2017 and held it in 6 quarters.
  • RBC Europe's Portola Pharmaceuticals, Inc. position peaked at $27K in Q3 2017.
  • 209 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2019.

Based on RBC Europe's 13F filing for Q1 2019, filed 9 Nov 2023.